SGLT2 Inhibitor Use Linked to Lower Risk for Heart Failure, Death in Type 2 Diabetes
There was no association between initiation of SGLT2 inhibitors and other glucose-lowering drugs and the onset of atrial fibrillation.
For patients with type 2 diabetes mellitus (T2DM), travel costs relating to hemoglobin A1c (HbA1c) screening constitute a substantial cost item, and self-monitoring can reduce costs.
Finnish investigators evaluated the link between diabetes medications other than DPP-4 inhibitors and the risk for BP.
Investigators examined whether β-cell function can be improved or preserved with antihyperglycemic agents in young patients.